SCHEMBL3384264

SCHEMBL3384264

CS(=O)(=O)N1CCC(Nc2nc(N)c(C(=O)c3c(F)cccc3F)s2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 13/20 0.64
CDK4 P11802 13/20 0.64
CCND1 P24385 13/20 0.64
CDK1 P06493 9/20 0.64
CDK5 Q00535 3/20 0.52
CDK5R1 Q15078 2/20 0.52
CDK9 P50750 5/20 0.52
CDK6 Q00534 5/20 0.52
CDK11A Q9UQ88 5/20 0.52
CCNT1 O60563 4/20 0.52
CCNA2 P20248 4/20 0.49
CASK O14936 1/20 0.47
ROCK2 O75116 1/20 0.47
CDKL5 O76039 1/20 0.47
STK10 O94804 1/20 0.47
CDK14 O94921 1/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
MAK P20794 1/20 0.47
CDK11B P21127 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6198732 0.94 CDK4 (0.57) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6195586 0.94 CDK4 (0.57) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6198310 0.92 CDK5 (0.54) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6216994 0.90 CDK4 (0.52) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6196763 0.90 CDK4 (0.52) CDK2CDK4CCND1CDK1CDK5
SCHEMBL14073871 0.89 CDK2 (0.55) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6407196 0.89 CDK4 (0.52) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6198789 0.89 CDK2 (0.51) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6407347 0.89 CDK4 (0.58) CDK2CDK4CCND1CDK1CDK5
SCHEMBL6197032 0.88 CDK4 (0.63) CDK2CDK4CCND1CDK1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1771424-B1 NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-15 EP claimed
US-7423053-B2 4-Aminothiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US claimed
EP-1771424-A1 NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-04-11 EP claimed
US-20060014958-A1 4-Aminothiazole derivatives CHEN LI 2006-01-19 US claimed
WO-2006005508-A1 NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-19 WO claimed
EP-1771424-B1 NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-15 EP disclosed
EP-1771424-B1 NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-15 EP disclosed
CN-1976910-B 2, 4-diaminothiazol-5-one derivatives HOFFMANN LA ROCHE 2010-07-21 CN disclosed
US-20100002569-A1 OPTICAL INFORMATION RECORDING MEDIUM, METHOD OF RECORDING AND REPRODUCING INFORMATION, AND AZO METAL COMPLEX DYE FUJIFILM CORPORATION (JP) 2010-01-07 US disclosed
US-7423053-B2 4-Aminothiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423053-B2 4-Aminothiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
US-7423053-B2 4-Aminothiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-09 US disclosed
CN-1976910-A Novel 2, 4-diaminothiazol-5-one derivatives HOFFMANN LA ROCHE (CH) 2007-06-06 CN disclosed
EP-1771424-A1 NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2007-04-11 EP disclosed
US-20060014958-A1 4-Aminothiazole derivatives CHEN LI 2006-01-19 US disclosed
WO-2006005508-A1 NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-01-19 WO disclosed
EP-1597256-A1 N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS PFIZER INC. (US) 2005-11-23 EP disclosed
US-20050101595-A1 N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use PFIZER INC. 2005-05-12 US disclosed
WO-2004074283-A1 N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS PFIZER INC. (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014958-A1 4-Aminothiazole derivatives CDK4, CDK2, CCNI CDK2 2/4885CDK4 1/4885CCND1 36/4885
US-20050101595-A1 N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use CCNI, MKI67, TK1 CDK2 6/4885CDK4 78/4885CCND1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.